Cargando…

Albumin‐myosteatosis gauge as a novel prognostic risk factor in patients with non‐metastatic colorectal cancer

BACKGROUND: Myosteatosis and systemic inflammation are well‐known prognostic factors in patients with colorectal cancer (CRC). The serum albumin level is a reflection of malnutrition and systemic inflammation, which in turn plays a key role in the development of myosteatosis. However, few studies ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yerim, Lee, Jae‐Hoon, Cho, Eun‐Suk, Lee, Hye Sun, Shin, Su‐Jin, Park, Eun Jung, Baik, Seung Hyuk, Lee, Kang Young, Kang, Jeonghyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067505/
https://www.ncbi.nlm.nih.gov/pubmed/36696881
http://dx.doi.org/10.1002/jcsm.13183
_version_ 1785018487191633920
author Kim, Yerim
Lee, Jae‐Hoon
Cho, Eun‐Suk
Lee, Hye Sun
Shin, Su‐Jin
Park, Eun Jung
Baik, Seung Hyuk
Lee, Kang Young
Kang, Jeonghyun
author_facet Kim, Yerim
Lee, Jae‐Hoon
Cho, Eun‐Suk
Lee, Hye Sun
Shin, Su‐Jin
Park, Eun Jung
Baik, Seung Hyuk
Lee, Kang Young
Kang, Jeonghyun
author_sort Kim, Yerim
collection PubMed
description BACKGROUND: Myosteatosis and systemic inflammation are well‐known prognostic factors in patients with colorectal cancer (CRC). The serum albumin level is a reflection of malnutrition and systemic inflammation, which in turn plays a key role in the development of myosteatosis. However, few studies have been conducted on these synergistic effects. This study aimed to examine the individual and synergistic effects of different prognostic markers related to skeletal muscle quality and serum albumin levels in patients with CRC. METHODS: This study enrolled patients with stage I–III CRC who underwent surgical resection between July 2006 and February 2014. Skeletal muscle index (SMI) and skeletal muscle radiodensity (SMD) were calculated using computed tomography at the L3 level obtained within 2 months prior to surgery. The albumin‐myosteatosis gauge (AMG) was defined as SMD × albumin. Patients were divided into sex‐specific quartiles (G1 to G4) according to the AMG, and analysis of variance for continuous variables and chi‐square test for categorical variables were used to compare variables among quartiles. Cox proportional hazard models were constructed and integrated receiver operating characteristic curve (iAUC) analysis was used to compare the prognostic performance of SMD, albumin and AMG. RESULTS: Among the 906 participants, the median (interquartile) age was 64 (55–72) years, and 365 (40.3%) were female. AMG was significantly correlated with the occurrence of complications, albumin level, SMI and SMD (all P < 0.001). Overall survival (OS) differed significantly according to the AMG group, with 5‐year OS for G1–G4 being 73.4%, 86.2%, 91.1% and 95.5%, respectively (P < 0.0001). Although SMI, SMD, albumin and AMG were all significant individual prognostic markers of OS in the univariable analysis, AMG remained the only independent prognostic factor in the multivariable analysis (G1 vs. G2, P = 0.045, G1 vs. G3, P = 0.005, G1 vs. G4, P < 0.001, respectively). The iAUC value of AMG [0.681, 95% confidence interval (CI) = 0.638–0.723] was superior to that of SMD (0.610, 95% CI = 0.566–0.654) (bootstrap iAUC mean difference = 0.071, 95% CI = 0.034–0.106), SMI (0.551, 95% CI = 0.511–0.594) (bootstrap iAUC mean difference = 0.129, 95% CI = 0.076–0.181) and albumin (0.627, 95% CI = 0.585–0.668) (bootstrap iAUC mean difference = 0.053, 95% CI = 0.010–0.098). CONCLUSIONS: In patients with stage I–III CRC, AMG is a meaningful predictor of survival, with superior prognostic value compared to SMI, SMD or albumin alone. Further studies are needed to determine their significance in different ethnic groups.
format Online
Article
Text
id pubmed-10067505
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100675052023-04-04 Albumin‐myosteatosis gauge as a novel prognostic risk factor in patients with non‐metastatic colorectal cancer Kim, Yerim Lee, Jae‐Hoon Cho, Eun‐Suk Lee, Hye Sun Shin, Su‐Jin Park, Eun Jung Baik, Seung Hyuk Lee, Kang Young Kang, Jeonghyun J Cachexia Sarcopenia Muscle Original Articles BACKGROUND: Myosteatosis and systemic inflammation are well‐known prognostic factors in patients with colorectal cancer (CRC). The serum albumin level is a reflection of malnutrition and systemic inflammation, which in turn plays a key role in the development of myosteatosis. However, few studies have been conducted on these synergistic effects. This study aimed to examine the individual and synergistic effects of different prognostic markers related to skeletal muscle quality and serum albumin levels in patients with CRC. METHODS: This study enrolled patients with stage I–III CRC who underwent surgical resection between July 2006 and February 2014. Skeletal muscle index (SMI) and skeletal muscle radiodensity (SMD) were calculated using computed tomography at the L3 level obtained within 2 months prior to surgery. The albumin‐myosteatosis gauge (AMG) was defined as SMD × albumin. Patients were divided into sex‐specific quartiles (G1 to G4) according to the AMG, and analysis of variance for continuous variables and chi‐square test for categorical variables were used to compare variables among quartiles. Cox proportional hazard models were constructed and integrated receiver operating characteristic curve (iAUC) analysis was used to compare the prognostic performance of SMD, albumin and AMG. RESULTS: Among the 906 participants, the median (interquartile) age was 64 (55–72) years, and 365 (40.3%) were female. AMG was significantly correlated with the occurrence of complications, albumin level, SMI and SMD (all P < 0.001). Overall survival (OS) differed significantly according to the AMG group, with 5‐year OS for G1–G4 being 73.4%, 86.2%, 91.1% and 95.5%, respectively (P < 0.0001). Although SMI, SMD, albumin and AMG were all significant individual prognostic markers of OS in the univariable analysis, AMG remained the only independent prognostic factor in the multivariable analysis (G1 vs. G2, P = 0.045, G1 vs. G3, P = 0.005, G1 vs. G4, P < 0.001, respectively). The iAUC value of AMG [0.681, 95% confidence interval (CI) = 0.638–0.723] was superior to that of SMD (0.610, 95% CI = 0.566–0.654) (bootstrap iAUC mean difference = 0.071, 95% CI = 0.034–0.106), SMI (0.551, 95% CI = 0.511–0.594) (bootstrap iAUC mean difference = 0.129, 95% CI = 0.076–0.181) and albumin (0.627, 95% CI = 0.585–0.668) (bootstrap iAUC mean difference = 0.053, 95% CI = 0.010–0.098). CONCLUSIONS: In patients with stage I–III CRC, AMG is a meaningful predictor of survival, with superior prognostic value compared to SMI, SMD or albumin alone. Further studies are needed to determine their significance in different ethnic groups. John Wiley and Sons Inc. 2023-01-25 /pmc/articles/PMC10067505/ /pubmed/36696881 http://dx.doi.org/10.1002/jcsm.13183 Text en © 2023 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Kim, Yerim
Lee, Jae‐Hoon
Cho, Eun‐Suk
Lee, Hye Sun
Shin, Su‐Jin
Park, Eun Jung
Baik, Seung Hyuk
Lee, Kang Young
Kang, Jeonghyun
Albumin‐myosteatosis gauge as a novel prognostic risk factor in patients with non‐metastatic colorectal cancer
title Albumin‐myosteatosis gauge as a novel prognostic risk factor in patients with non‐metastatic colorectal cancer
title_full Albumin‐myosteatosis gauge as a novel prognostic risk factor in patients with non‐metastatic colorectal cancer
title_fullStr Albumin‐myosteatosis gauge as a novel prognostic risk factor in patients with non‐metastatic colorectal cancer
title_full_unstemmed Albumin‐myosteatosis gauge as a novel prognostic risk factor in patients with non‐metastatic colorectal cancer
title_short Albumin‐myosteatosis gauge as a novel prognostic risk factor in patients with non‐metastatic colorectal cancer
title_sort albumin‐myosteatosis gauge as a novel prognostic risk factor in patients with non‐metastatic colorectal cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067505/
https://www.ncbi.nlm.nih.gov/pubmed/36696881
http://dx.doi.org/10.1002/jcsm.13183
work_keys_str_mv AT kimyerim albuminmyosteatosisgaugeasanovelprognosticriskfactorinpatientswithnonmetastaticcolorectalcancer
AT leejaehoon albuminmyosteatosisgaugeasanovelprognosticriskfactorinpatientswithnonmetastaticcolorectalcancer
AT choeunsuk albuminmyosteatosisgaugeasanovelprognosticriskfactorinpatientswithnonmetastaticcolorectalcancer
AT leehyesun albuminmyosteatosisgaugeasanovelprognosticriskfactorinpatientswithnonmetastaticcolorectalcancer
AT shinsujin albuminmyosteatosisgaugeasanovelprognosticriskfactorinpatientswithnonmetastaticcolorectalcancer
AT parkeunjung albuminmyosteatosisgaugeasanovelprognosticriskfactorinpatientswithnonmetastaticcolorectalcancer
AT baikseunghyuk albuminmyosteatosisgaugeasanovelprognosticriskfactorinpatientswithnonmetastaticcolorectalcancer
AT leekangyoung albuminmyosteatosisgaugeasanovelprognosticriskfactorinpatientswithnonmetastaticcolorectalcancer
AT kangjeonghyun albuminmyosteatosisgaugeasanovelprognosticriskfactorinpatientswithnonmetastaticcolorectalcancer